How much cash does Kalaris Therapeutics, Inc. Common Stock generate?

Kalaris Therapeutics, Inc. Common Stock (KLRS) generated -$42.5M in operating cash flow over the trailing twelve months.

What is Kalaris Therapeutics, Inc. Common Stock's free cash flow?

After $36.5K of capital expenditures, Kalaris Therapeutics, Inc. Common Stock's free cash flow was -$86.8M over the trailing twelve months.

Where does Kalaris Therapeutics, Inc. Common Stock's cash flow data come from?

Every line is extracted from Kalaris Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Kalaris Therapeutics, Inc. Common Stock KLRS Cash Flow Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	Q1 '26	Q4 '25	Q3 '25	Q2 '25	Q1 '25
Net income	-$10.86M-6.5%	-$10M+54.6%	-$11.89M+68.8%	-$11.35M-101%	-$10.2M-199%
Depreciation and amortization	$10K—	$10K—	——	——	——
Stock-based compensation	$580K+55.1%	$333K+18.9%	$638K+144%	$591K+83.5%	$374K+1,106%
Change in accounts payable	-$376K-140%	——	-$3.2M—	$1.31M+319%	$934K+176%
Change in accrued liabilities	$120K+1,600%	$1.73M+159%	$1.49M+553%	-$1.07M-1,968%	-$8K+97.1%
Change in other assets	$810K+157%	$0-100%	$89K-79.6%	$1.7M—	-$1.42M-1,064%
Change in operating lease liabilities	-$37K—	-$98K—	——	——	——
Net cash from operating activities	-$11.58M-55.6%	-$7.06M+10.1%	-$11.33M-162%	-$12.54M-216%	-$7.44M-64.6%
Purchases of investments	$70.35M+715%	$8.63M—	$8.63M—	$8.63M—	$8.63M—
Proceeds from maturities/sales of investments	$20M+433%	$3.75M-25.0%	$3.75M-81.3%	$3.75M-87.5%	$3.75M-90.6%
Net cash from investing activities	-$50.35M-921%	-$4.93M-199%	-$4.93M-125%	-$4.93M-116%	-$4.93M-112%
Proceeds from issuance of common stock	$74K-99.3%	$10.5M+524,900%	$10.5M—	$10.5M—	$10.5M—
Net cash from financing activities	-$1.7M-102%	$47.74M+530%	——	——	$107.27M+1,530%
Net increase (decrease) in cash	-$63.63M-164%	$55.67M+20,416%	——	——	$99.83M+4,751%
Accretion (Amortization) of Discounts and Premiums, Investments	$220K—	$316K+5,167%	——	——	——
Change In Fair Value Of Derivative Liability	$0-100%	$0-100%	$0-100%	$0-100%	$1.23M—
Change In Fair Value Of Tranche Liability	$0-100%	$0-100%	$0—	$0—	$365K—
Depreciation	$10K—	$10K—	——	——	——
Gain Loss On Extinguishment And On Issuance Of Convertible Promissory Notes	——	——	——	——	-$186K—
Accrued expenses and other liabilities	$120K+1,600%	$1.73M+159%	$151K+120%	$276K+106%	-$8K-111%
Operating lease liabilities	-$37K—	-$98K—	——	——	——
Increase (Decrease) in Prepaid Expense and Other Assets	$34K+102%	-$357K-149%	-$2.04M—	$2.01M+25,000%	-$1.42M-459%
Non Cash Interest Expense	——	——	——	——	$1.44M+1,750%
Non Cash Operating Lease Income Expense	-$42K—	-$41K—	——	——	——
Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale	$20M+433%	$3.75M-25.0%	$3.75M-81.3%	$3.75M-87.5%	$3.75M-90.6%
Payment Of Deferred Transaction Costs And Issuance Costs	$1.77M-24.6%	$591K-75.4%	——	——	$2.35M+46,820%
Payments Of Stock Issuance Costs	——	$417.25K—	$417.25K—	$417.25K—	$417.25K—
Proceeds From Cash Acquired In Connection With Merger	——	——	——	——	$102.11M—
Common stock issuance for private placement	——	$2M—	$2M—	$2M—	$2M—
Available For Sale Debt Securities Gross Unrealized Gain	——	$1.5K—	$1.5K—	$1.5K—	$1.5K—
Value of common stock issued to settle convertible senior notes	——	——	——	——	$3.7M—
Debt Conversion Original Debt Amount1	——	——	——	——	$20.8M—
Increase Decrease In Operating Lease Liability	-$37K—	-$98K—	——	——	——
Proceeds From Notes Payable	——	——	——	——	$7.5M+50.2%
Issuances of common stock from employee benefit plans receivable	——	——	——	——	$49.69M—
Deferred Transaction And Financing Issuance Costs Included In Accounts Payable And Accrued Expenses And Other Current Liabilities	$337K-46.4%	——	——	——	$629K+236%
Issuance Of Common Stock And Equity Elimination In Connection With The Merger	——	——	——	——	$104.99M—
Merger Transaction Costs Recognized In Additional Paid In Capital	——	——	——	——	$5.36M—
Premium On Issuance Of Convertible Promissory Notes	——	——	——	——	$186K-95.5%
Repurchase Of Common Stock Shares For Royalty Obligation	——	——	——	——	——
Vesting Of Restricted Stock Awards	——	——	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Kalaris Therapeutics, Inc. Common Stock generate?: Kalaris Therapeutics, Inc. Common Stock (KLRS) generated -$42.5M in operating cash flow over the trailing twelve months.
What is Kalaris Therapeutics, Inc. Common Stock's free cash flow?: After $36.5K of capital expenditures, Kalaris Therapeutics, Inc. Common Stock's free cash flow was -$86.8M over the trailing twelve months.
Where does Kalaris Therapeutics, Inc. Common Stock's cash flow data come from?: Every line is extracted from Kalaris Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.